Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 3NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 242Gastrointestinal 54Tumor-Agnostic 13Thoracic 12CNS 10Gynecologic 8Head & Neck 6Genitourinary 6Other solid neoplasm 4Sarcoma 2Dermatologic 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 85Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Trastuzumab × Lymphoid × Clear all
NCT03013218 2025-08-01

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

ALX Oncology Inc.

Phase 1 Completed
174 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡